Delving into the Latest Updates on Millmount Healthcare Ltd. with Synapse

Overview

Tags

Neoplasms

Other Diseases

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Monoclonal antibody	1

Top 5 Target	Count

GD2(Disialoganglioside GD2)	1

本研究将收集达妥昔单抗β药品上市后在真实医疗环境中治疗高危神经母细胞瘤患者的数据，评估在维持治疗阶段使用达妥昔单抗β与常规治疗方案的有效性和安全性。研究结果将桥接境外临床研究数据，用于支持达妥昔单抗β获得最终完全的批准。

[Translation]

This study will collect data on the treatment of high-risk neuroblastoma patients in real medical settings after the launch of datuximab beta, and evaluate the effectiveness and safety of using datuximab beta in the maintenance treatment phase compared with conventional treatment regimens. The results of the study will bridge the overseas clinical research data to support the final full approval of datuximab beta.

Start Date03 Jun 2022

Sponsor / Collaborator

EUSA Pharma (Netherlands) B.V.

[+3]

100 Clinical Results associated with Millmount Healthcare Ltd.

Login to view more data

0 Patents (Medical) associated with Millmount Healthcare Ltd.

Login to view more data

100 Deals associated with Millmount Healthcare Ltd.

Login to view more data

100 Translational Medicine associated with Millmount Healthcare Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 19 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1

1

Login to view more data